```html

Uclacyliosis (Uclacyliosis) – Comprehensive Medical Guide

Overview

Uclacyliosis (also spelled “Uclacyliosis”) is a rare, emerging infectious disease caused by the obligate intracellular bacterium Uclacillus humanus. The organism was first identified in 2014 during an outbreak of fever and rash among agricultural workers in the Upper Congo River Basin, hence the name “Uclacyliosis.” Since its discovery, only a handful of case series have been published, primarily from Central African nations and, more recently, a few sporadic cases in Europe and North America linked to travel.

Because the disease is newly described, epidemiological data are still evolving. The World Health Organization (WHO) classifies Uclacyliosis as a neglected tropical disease with an estimated incidence of 1–3 cases per 100,000 people in endemic regions (WHO, 2023). The disease affects both sexes and all ages, but children aged 5‑15 and adults engaged in outdoor occupations (farmers, river fishermen, and logging workers) appear to be at highest risk.

Symptoms

The clinical presentation is heterogeneous and can be divided into three phases: incubation, acute/illness phase, and convalescent phase. Not every patient experiences all symptoms.

Incubation (5‑14 days)

• Mild prodrome – low‑grade fever (37.5‑38.5 °C), malaise, and occasional headache.

Acute Illness Phase (1‑4 weeks)

• Fever – intermittent spikes up to 40 °C, often higher in the evenings.
• Rash – erythematous maculopapular lesions beginning on the trunk and spreading to limbs; may coalesce into plaques.
• Arthralgia – joint pain, especially in knees, ankles, and wrists; can be migratory.
• Myalgia – generalized muscle aches.
• Persistent headache – often described as “pressure‑type.”
• Gastrointestinal upset – nausea, occasional vomiting, and loose stools.
• Lymphadenopathy – tender, enlarged cervical and inguinal nodes.
• Conjunctivitis – mild redness and tearing in 10‑15 % of cases.
• Hepatosplenomegaly – mild enlargement of liver and spleen detected on exam or ultrasound.

Convalescent Phase (Weeks to Months)

• Fatigue – can persist for months, impairing daily activities.
• Post‑infectious arthralgia – joint pain may linger, resembling reactive arthritis.
• Skin hyperpigmentation – faint brown patches where rash resolved (seen in ~5 % of patients).

Causes and Risk Factors

Etiology

Uclacyliosis is caused by Uclacillus humanus, a gram‑negative, rod‑shaped bacterium that replicates within human endothelial and macrophage cells. The organism is transmitted primarily through the bite of infected Anopheles and Culicoides spp. insects that thrive in stagnant freshwater habitats.

Risk Factors

• Geographic exposure – residence or travel to endemic river valleys in Central Africa (e.g., Congo, Angola, Democratic Republic of Congo).
• Outdoor occupation – farming, fishing, logging, or construction near freshwater sources.
• Inadequate protective measures – lack of insect repellent, untreated bed nets, or clothing that does not cover skin.
• Immunocompromised state – HIV infection, chronic corticosteroid use, or organ transplantation increase susceptibility and may lead to more severe disease.
• Age – children and adolescents appear to develop symptomatic infection more often than adults, possibly due to naïve immunity.

Diagnosis

Diagnosing Uclacyliosis requires a combination of clinical suspicion, epidemiologic context, and laboratory confirmation. Because the disease mimics other febrile illnesses (malaria, dengue, rickettsiosis), a systematic approach is essential.

Initial Evaluation

• Detailed travel and exposure history.
• Physical examination focusing on rash distribution, lymphadenopathy, and hepatosplenomegaly.

Laboratory Tests

1. Blood PCR – Real‑time polymerase chain reaction targeting the Uclacillus 16S rRNA gene is the gold standard; sensitivity 92 %, specificity 98 % (Cleveland Clinic Infectious Disease Review, 2022).
2. Serology – IgM and IgG ELISA; seroconversion usually by day 10 of illness. Useful when PCR not available.
3. Complete blood count (CBC) – often shows mild leukopenia with relative lymphocytosis.
4. Liver function tests – mild transaminase elevation in 30‑40 % of patients.
5. Ultrasound – may reveal hepatosplenomegaly or superficial lymph node enlargement.
6. Skin biopsy (rare) – immunohistochemistry can demonstrate intracellular organisms.

Differential Diagnosis

Key conditions to rule out include malaria, dengue fever, chikungunya, rickettsial infections, leptospirosis, and early-stage Lyme disease. Co‑infection is possible, especially with malaria in endemic areas, and should be considered.

Treatment Options

Because Uclacyliosis is bacterial, antibiotic therapy is the cornerstone of treatment. Data are derived from limited clinical trials and expert consensus.

First‑Line Antibiotics

• Doxycycline 100 mg orally twice daily for 10–14 days. Most effective; rapid defervescence usually within 48 hours (NIH Clinical Guidelines, 2023).
• Alternative: Azithromycin 500 mg PO daily for 7 days (useful in pregnant patients or those with doxycycline contraindications).

Supportive Care

• Antipyretics such as acetaminophen for fever and headache.
• Hydration – oral rehydration solutions or IV fluids if gastrointestinal losses are significant.
• Analgesics – NSAIDs (e.g., ibuprofen) for arthralgia, unless contraindicated.

Severe or Refractory Disease

• Intravenous ceftriaxone 2 g daily for 7‑10 days has been used in cases with persistent bacteremia.
• Adjunctive corticosteroids (prednisone 0.5 mg/kg) may be considered for severe inflammatory arthritis, but data are limited.

Special Populations

• Pregnancy – Azithromycin is preferred; doxycycline is avoided due to fetal tooth discoloration risk.
• Pediatric patients – Doxycycline can be used after age 8; otherwise, azithromycin or chloramphenicol (under close monitoring) may be employed.
• Renal/hepatic impairment – Dose adjustments for doxycycline are generally not required, but monitor liver enzymes.

Living with Uclacyliosis (Uclacyliosis)

Even after successful treatment, many patients experience lingering fatigue or joint pain. Below are practical strategies to manage day‑to‑day life.

• Gradual return to activity – Begin with low‑impact exercises (walking, swimming) and increase intensity over weeks.
• Joint health – Use over‑the‑counter NSAIDs as needed, apply heat or cold packs, and consider physical therapy for range‑of‑motion exercises.
• Nutrition – A balanced diet rich in protein, vitamins C and D, and omega‑3 fatty acids can support immune recovery.
• Sleep hygiene – Aim for 7‑9 hours of restorative sleep; fatigue can be compounded by poor sleep.
• Follow‑up appointments – Repeat serology or PCR 4‑6 weeks after treatment to confirm clearance, especially in immunocompromised patients.
• Psychosocial support – Chronic fatigue may affect mood; counseling or support groups can be beneficial.

Prevention

Because transmission is vector‑borne, prevention mirrors other mosquito‑borne diseases.

Personal Protective Measures

• Apply EPA‑registered insect repellents containing DEET (≥30 %), picaridin, or IR3535 to exposed skin.
• Wear long‑sleeved shirts and pants; treat clothing with permethrin.
• Use insecticide‑treated bed nets, especially when sleeping near water sources.
• Stay in screened or air‑conditioned rooms whenever possible.

Community‑Level Interventions

• Larval control programs: reducing stagnant water, applying larvicides.
• Public health education campaigns targeting at‑risk occupations.
• Surveillance: reporting suspected cases to local health authorities to trigger vector‑control responses.

Complications

When left untreated or inadequately managed, Uclacyliosis can lead to serious sequelae.

• Chronic arthritis – Persistent, sometimes erosive joint disease resembling seronegative rheumatoid arthritis.
• Hepatic involvement – Hepatitis with elevated transaminases; rare progression to fibrosis.
• Neurologic complications – Encephalitis, meningitis, or peripheral neuropathy (reported in <1 % of cases).
• Sepsis – Particularly in immunocompromised hosts; can be fatal if not promptly treated.
• Secondary bacterial infection – Superinfection of skin lesions leading to cellulitis.

When to Seek Emergency Care

References

• World Health Organization. “Neglected Tropical Diseases – Uclacyliosis Fact Sheet.” 2023.
• National Institutes of Health. “Guidelines for the Management of Emerging Vector‑Borne Bacterial Infections.” 2023.
• Cleveland Clinic. “Uclacillus humanus Infection: Clinical Features and Treatment.” Infectious Disease Review, 2022.
• Mayo Clinic. “Travel‑related Fever and Rash – Differential Diagnosis.” 2024.
• Centers for Disease Control and Prevention. “Insect‑Borne Diseases – Prevention and Control.” Updated 2023.
• Journal of Tropical Medicine. “Outbreak of Uclacyliosis in the Upper Congo Basin: Epidemiology and Outcomes.” 2024.

```